Holen Sie sich die Stockscreener-App
1.26
1.61%
0.02
Schlusskurs vom Vortag:
$1.24
Offen:
$1.23
24-Stunden-Volumen:
60,607
Relative Volume:
0.18
Marktkapitalisierung:
$23.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.08M
KGV:
-0.4286
EPS:
-2.94
Netto-Cashflow:
$-25.68M
1W Leistung:
+3.28%
1M Leistung:
+18.12%
6M Leistung:
-27.59%
1J Leistung:
+54.79%
1-Tages-Spanne:
$1.23
$1.29
1-Wochen-Bereich:
$1.148
$1.3099
52-Wochen-Spanne:
$0.7801
$2.55
Chemomab Therapeutics Ltd Adr Stock (CMMB) Company Profile
Firmenname
Chemomab Therapeutics Ltd Adr
Sektor
Branche
Telefon
972-77-331-0156
Adresse
KIRYAT ATIDIM, BUILDING 7, TEL AVIV
Vergleichen Sie CMMB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMMB
Chemomab Therapeutics Ltd Adr
|
1.26 | 23.01M | 0 | -33.08M | -25.68M | -2.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Chemomab Therapeutics Ltd Adr Stock (CMMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-13 | Eingeleitet | Maxim Group | Buy |
| 2024-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-12-19 | Fortgesetzt | ROTH MKM | Buy |
Chemomab Therapeutics Ltd Adr Aktie (CMMB) Neueste Nachrichten
Chemomab Leadership Changes Signal Strategic Momentum Following Positive Clinical Results - Barchart.com
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com
Microsoft Stock After Xbox Price Hike: Buy Or Hold? - Barchart.com
Should You Buy, Sell, Or Hold Nio Stock Amid Firefly Brand Launch? - Barchart.com
UBS Group Q1 Earnings & Revenues Dip Y/Y, Credit Loss Expenses Slip - Barchart.com
This ‘Strong Buy’ Robotaxi Stock Just Got A Huge Bump. Should You Buy Shares Now? - Barchart.com
Chemomab reports promising PSC treatment data - Investing.com
Chemomab Announces New Medical And Clinical Appointments - Barchart.com
Should You Buy Tesla Stock On The ‘Liberation Day’ Dip? - Barchart.com
Should You Dump Tesla Stock As Deliveries Plunge In Q1 And Tariff Fears Escalate? - Barchart.com
The Aurora Cannabis Inc (NASDAQ: ACB) Stock Price: Is It Overvalued? - Stocks Register
How Stable And Growing Is Globavend Holdings Ltd (NASDAQ: GVH)? - Stocks Register
Before Buying AYRO Inc (NASDAQ: AYRO) Stock, Read This First - Stocks Register
Is Advance Auto Parts Inc (NYSE: AAP) A Good Investment For New Investors Now? - stocksregister.com
Nu Holdings Ltd (NYSE: NU) Has Great Upside Potential - stocksregister.com
ZEEKR Intelligent Technology Holding Ltd. ADR (NYSE: ZK): Getting A Free Pass? - stocksregister.com
AT&T, Inc (NYSE: T) Jumps 1.59%: What Could Be On The Way Going Forward? - Stocks Register
Adma Biologics Inc (NASDAQ: ADMA): Blank Check For Growth? - Stocks Register
A Bullish 2025 Outlook For Blink Charging Co (NASDAQ: BLNK) Shares - Stocks Register
In 2025, Linkers Industries Ltd (NASDAQ: LNKS) Shares Will Likely Be Bullish - Stocks Register
Carrier Global Corp (NYSE: CARR): On Track To A Higher Share Price - Stocks Register
Before Buying Avantor Inc (NYSE: AVTR) Stock, Read This First - stocksregister.com
Ally Financial Inc (NYSE: ALLY): An Enticing Stock To Watch - stocksregister.com
Nebokitug shows promise in PSC treatment trial - Investing.com
Q3 Rundown: Sea (NYSE:SE) Vs Other Online Marketplace Stocks - Barchart.com
Does DLocal Limited (NASDAQ: DLO) Still Need To Convince Analysts? - stocksregister.com
Think You Need A Good Stock? Look At This Scilex Holding Company (NASDAQ: SCLX) Analysis - stocksregister.com
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - stocksregister.com
Is WeRide Stock A Buy, Sell, Or Hold As Nvidia Reveals Its $25 Million Bet? - Barchart.com
Chemomab Therapeutics (CMMB) Stock Price, News & Analysis - MarketBeat
How analysts predict Chemomab Therapeutics Ltd ADR (CMMB) will perform this quarter? - US Post News
Nebokitug positioned as potential first FDA-approved PSC treatment By Investing.com - Investing.com South Africa
Arm Just Nabbed A Major Chip Deal With Meta. Is ARM Stock A Buy, Sell, Or Hold Now? - Barchart.com
Nvidia Sends Chinese Self-Driving Stock Up 100%, While Soundhound AI Sells Off - Barchart.com
Up 175% In 2024, Can This Growth Stock Keep Climbing? - Barchart.com
3 Stocks To Benefit From China’s Rare Earth Export Ban On U.S. - Barchart.com
LogicMark Inc (LGMK) Recovers 0.71% From Low: Are We There Yet? - Stocks Register
Is Toyota Stock A Buy, Sell, Or Hold On New Return On Equity Plans? - Barchart.com
3 Pharma Stocks To Buy As California Sounds The Alarm On Bird Flu Cases - Barchart.com
What's Going On With Alibaba Stock? - Barchart.com
Up 47% Post-Election, Can Tesla Stock Keep Soaring? - Barchart.com
Under Trump, European Defense Stocks Will Soar. Here's How To Invest. - Barchart.com
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewswire Inc.
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Investing.com
3 ETFs To Invest In The Data Center Boom - Barchart.com
NIO Stock Forecast: Is It All Over For This EV Stock, Or Will NIO Recover In 2025? - Barchart.com
Tesla Stock Forecast: Is The Worst Over For TSLA In 2024? - Barchart.com
1 Apple Supplier To Buy On Its Solid-State Battery Breakthrough - Barchart.com
5 AI Stocks That Still Look Undervalued - Barchart.com
3 Small-Cap Stocks To Invest In AI Drug Development - Barchart.com
symbol__ Stock Quote Price and Forecast - CNN
Finanzdaten der Chemomab Therapeutics Ltd Adr-Aktie (CMMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):